‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis

(2019) Srikanth Muppidi et al.   MUSCLE & NERVE

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis

(2019) Gérard Socié et al.   BRITISH JOURNAL OF HAEMATOLOGY

Correlation between myasthenia gravis−activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti−acetylcholine receptor antibody−positive refractory generalized myasthenia gravis in the phase 3 regain study

(2018) John Vissing et al.   MUSCLE & NERVE

Burden of illness in patients with treatment refractory myasthenia gravis

(2018) Nicole M. Engel-Nitz et al.   MUSCLE & NERVE

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

(2017) James F Howard et al.   LANCET NEUROLOGY

QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis

(2017) James F. Howard et al.   MUSCLE & NERVE

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

(2015) Christoph Licht et al.   KIDNEY INTERNATIONAL

Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis

(2015) Katherine A. Buzzard et al.   MUSCLE & NERVE

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

(2013) C.M. Legendre et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

(2012) Julien Zuber et al.   Nature Reviews Nephrology

MG-ADL: Still a relevant outcome measure

(2011) Srikanth Muppidi et al.   MUSCLE & NERVE

Response of patients with refractory myasthenia gravis to rituximab: a retrospective study

(2011) Richard J. Nowak et al.   Therapeutic Advances in Neurological Disorders

Construct and concurrent validation of the MG-QOL15 in the practice setting

(2009) Ted M. Burns et al.   MUSCLE & NERVE

Rebooting the Immune System with High-Dose Cyclophosphamide for Treatment of Refractory Myasthenia Gravis

(2008) Daniel B. Drachman et al.   Annals of the New York Academy of Sciences

Less is more, or almost as much: A 15-item quality-of-life instrument for myasthenia gravis

(2008) Ted M. Burns et al.   MUSCLE & NERVE

Lifetime course of myasthenia gravis

(2007) David Grob et al.   MUSCLE & NERVE